| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Bad debt | NaN | 2,859 | NaN | NaN |
| Stock based compensation | NaN | NaN | NaN | 233,670 |
| Impairment of patent | NaN | 0 | 0 | 0 |
| Net loss | -111,086 | -2,292,450 | 1,089,602 | -355,050 |
| Change in fair value of derivative liabilities | 174,884 | -569,898 | -201,360 | 192,613 |
| Amortization of debt discount | 71,879 | 25,132 | 0 | 0 |
| Impairment of inventory | NaN | 0 | 0 | 0 |
| Management compensation | 105,000 | 105,000 | 338,670 | NaN |
| Amortization of prepaid expense | 0 | 0 | 0 | 0 |
| Depreciation | 1,500 | 1,500 | 1,500 | 1,000 |
| Gain on settlement of debt | NaN | 32,100 | 101,700 | NaN |
| Accounts receivable | NaN | 0 | 0 | 59 |
| Inventory | -1,738 | 478 | 4,654 | 20,459 |
| Prepaid expense | -1,875 | 6,250 | 0 | -100,000 |
| Accounts payable and accrued liabilities | 16,161 | 1,957 | 26,687 | 24,623 |
| Due to related party | 2,978 | NaN | NaN | NaN |
| Net cash used in operating activities | -84,839 | -155,828 | -151,309 | -208,888 |
| Purchase property and equipment's | NaN | 0 | 0 | 18,000 |
| Net cash used in investing activities | NaN | 0 | 0 | -18,000 |
| Proceeds from issuance of series d preferred stock | NaN | 0 | 0 | 300,000 |
| Proceeds from notes payable | NaN | 0 | 0 | 0 |
| Proceeds from convertible notes | NaN | 255,000 | NaN | NaN |
| Net cash provided by financing activities | NaN | 255,000 | 0 | 300,000 |
| Net change in cash | -84,839 | 99,172 | -151,309 | 73,112 |
| Cash at beginning of period | 158,445 | 59,273 | 137,470 | NaN |
| Cash at end of period | 73,606 | 158,445 | 59,273 | NaN |
BIOADAPTIVES, INC. (BDPT)
BIOADAPTIVES, INC. (BDPT)